MGI and Curetis Showcase Next-Generation Molecular Microbiology Solutions at 28th ECCMID
MGI and Curetis will be attending the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain, from 21–24 April 2018. Visit booth #79, hall 10, to learn more about their latest innovations.
At the conference, Curetis will introduce its new Unyvero UTI Application Cartridge for rapid syndromic testing of urinary tract infections, expected to receive CE-IVD marking in the near term. This addition complements Curetis’ portfolio of rapid molecular tests for severe infections, including CE-IVD applications for pneumonia (HPN), implant and tissue infections (ITI), bloodstream infections (BCU), intra-abdominal infections (IAI), and the recently U.S.-FDA cleared Unyvero LRT Application for lower respiratory tract infections.
Curetis will also update attendees on the Unyvero A30 RQ Analyzer and its first A30 RQ Application Cartridge, in development with expected CE-IVD marking in 2019. The A30 RQ Analyzer, designed for low- to mid-plex testing, complements the high-plex Unyvero A50 Analyzer, expanding the Unyvero Platform into a modular and flexible ‘any-plex’ solution for rapid molecular diagnostics.
Together with partner MGI Tech Co. Ltd (MGI), Shenzhen, China, Curetis will showcase a next-generation molecular microbiology package for automated detection of microbial pathogens and antibiotic resistance markers using next-generation sequencing (NGS). The sample-to-answer solution integrates MGI’s MGIFLP NGS workstation with Curetis’ sample preparation technology and Ares Genetics’ AMR data analytics. MGI representatives will be present at the booth to discuss the partnership and in-development package.
About Curetis
Curetis N.V. (Euronext: CURE) aims to be a leading provider of innovative molecular microbiology diagnostics, addressing the global challenge of diagnosing severe infections and antimicrobial resistance in hospitalized patients.
The Unyvero System is a fast, automated, cartridge-based platform for rapid detection of pathogens and antimicrobial resistance markers. Results are available within hours, compared to days or weeks with standard methods, improving patient outcomes, supporting antibiotic stewardship, and delivering economic benefits. Unyvero IVD products are marketed in Europe, the Middle East, Asia, and the U.S.
Curetis’ wholly owned subsidiary, Ares Genetics GmbH, offers next-generation solutions for infectious disease diagnostics and therapeutics. Its ARES Technology Platform combines the comprehensive ARESdb database of antimicrobial resistance genetics with advanced bioinformatics and artificial intelligence.
For more information, visit Curetis
